EPAS1 and neoplasm: DYRK1A could be especially relevant to the progression of glioblastoma since it has been also shown to control the ID2-HIF2α pathway, whereby the DYRK1A inhibition could block the HIF2α degradation and promote the tumor growth (Lee SB.